When word got out on August 26, 2024, that McKesson Corporation had agreed to pay $2.49 billion for a controlling interest in a unit of Florida Cancer Specialists & Research Institute (FCS), 1 the ...
Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on ...
Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few ...
Long-acting injectable HIV pre-exposure prophylaxis (LAI PrEP) could significantly reduce HIV infections, but disparate ...
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for ...
Chronic kidney disease (CKD) risk stratification that flagged high-risk patients in the electronic medical record, paired ...
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers. Across many disease ...
Sparsentan cut proteinuria about 70% and kept kidney function stable over 2 years in newly diagnosed IgA nephropathy in the SPARTAN study.
Weekly initiation of oral semaglutide among US adults eligible for obesity medications rose from nearly 0 to a peak of 4.56 ...
Incidence of major adverse cardiovascular events (MACE) declined across every income group in Denmark from 1988 to 2023, but ...
Infectious diseases (ID) and HIV clinicians can shape federal and state policy by pairing patient stories with sustained, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results